Clinical Researcher

Transgender and gender diverse individuals face an increased risk of cardiovascular disease (CVD). There is an unmet need to identify the root causes of CVD health disparities in this population. More research and evidence-based strategies are needed.

This article elucidates the multifaceted challenges impeding clinical trials, including patient recruitment, funding, and data management issues, while also highlighting the transformative potential of emerging technologies such as artificial intelligence (AI), blockchain, and genomic sequencing.

Clinical trials are critical for assessing new treatments in terms of their potential benefits for patients’ health and for their likelihood of financial success if marketed. Yet, the traditional approach focusing on a single primary endpoint may mean lengthy trials that often fail to capture the full spectrum of the treatment effects that are crucial to patient well-being

Technology is having an important positive impact on trials—from accelerating the collection of higher quality data to driving more real-time data monitoring and much more. Yet, despite technology’s abundant benefits, the introduction of disparate point systems into clinical trial settings has resulted in unforeseen burdens on sites.

Precision medicine brings about transformational advances in how we treat and prevent disease. While this development is overwhelmingly positive, especially for patients, it creates unintended challenges. As clinical sciences rapidly progress, the processes and technologies that are used to run trials have not kept pace. As a result, we endanger critical advancements in patient care.